Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

11 déc. 2018 08h30 HE | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors

CAMBRIDGE, Mass., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it appointed Mary Ann...
30 nov. 2018 18h00 HE | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Nov. 30, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2018,...
08 nov. 2018 19h13 HE | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Pricing of $500,000,000 Public Offering of Common Stock

CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, today announced that it has priced an...
07 nov. 2018 16h21 HE | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock

CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, today announced that it is offering to sell,...
02 nov. 2018 08h30 HE | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, today announced that management will present...
31 oct. 2018 18h00 HE | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, granted equity awards on October 31, 2018,...
24 oct. 2018 16h06 HE | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Developments

-- Third quarter 2018 EXONDYS 51® (eteplirsen) total net revenues of $78.5 million -- CAMBRIDGE, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in...
18 oct. 2018 16h30 HE | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics to Announce Third Quarter 2018 Financial Results and Recent Corporate Developments on October 24, 2018

CAMBRIDGE, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, will report third quarter 2018 financial...
15 oct. 2018 08h00 HE | Source: Sarepta Therapeutics, Inc.

Sarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate

-- Expands Sarepta’s portfolio to as many as 14 gene therapy programs -- -- Mucopolysaccharidosis type IIIA (MPS IIIA), also called Sanfilippo syndrome type A, is a rare, severe and fatal inherited...
08 oct. 2018 08h30 HE | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Paragon Bioservices, Greatly Enhancing its Commercial Capacity for Future Gene Therapies

CAMBRIDGE, Mass., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...

Page précédente